Black MS patients have poorer COVID-19 outcomes

In the North-American COViMS registry, Black MS patients have an increased risk for less favourable outcomes compared with White MS patients, even after adjusting for comorbidities at the time of COVID-19 [1]. COViMS is a North American clinician-based registry for MS patients with COVID-19. Cases are reported after 7 days and when the outcome of infection is reasonably certain. The main objectives of the registry are to see how MS patients as a group fare with COVID-19, and to evaluate how individual disease-modifying treatment (DMT) affects outcomes of COVID-19. The 2 race groups that were considered for the analysis that was presented as a late-breaking abstract were non-Hispanic White and Black or African-American (AA) patients with MS and clinically isolated syndrome (CIS). A total of 858 MS patients were reported in COViMS, 503 (58.6%) were reported as non-Hispanic White and 223 (26.0%) as Black/AA. The latter group were more likely to be youn...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 25 November, 2020